Myelofibrosis Danazol vs Momelotinib a JAK inhibitor H2 title H3 title 1st Thing You Will Learn In This Article 3rd Thing You Will Learn In This Article 4th Thing You Will Learn In This  It’s my pleasure today to discuss with you the results of the MOMENTUM study as presented to at this year’s EHA. So, the MOMENTUM study is an incredibly important study in the development of a drug called Momelotinib is a JAK inhibitor that differentiates itself from other JAK inhibitors that are already approved for the treatment of myelofibrosis. By a key off target effect on…
Author: Editor
Follow real-world patients on their cancer journeys as they and their multidisciplinary clinical teams navigate barriers to receiving treatment with immunotherapy. Complementing these stories are insights from experts on the underlying issues fueling disparate access to immunotherapies as well as strategies to overcome treatment barriers for patients in under-resourced communities. Visit https://www.cancercaredisparities.org/ to learn more or claim CME. Help close persistent immunotherapy access gaps to ensure your patients receive the best possible care. Supported by an educational grant from Bristol-Myers Squibb. Special thanks to: Carolyn Jones Productions, Thomas Jefferson University Hospital, and Einstein Medical Center Montgomery.
Pembrolizumab + Adoptive Cell Therapy Melanoma with T-Cell data. Tumor-infiltrating lymphocytes, and tumor-infiltrating lymphocytes recognize tumor antigens. We looked at predictive biomarkers in patients who have received adoptive cell therapy. So just in brief adoptive cell therapy is a fairly complex treatment modality. That’s been administered to patients with melanoma and other tumor types. The idea is that we resect a tumor. That harvest that harbors, both tumor cells and tumor-infiltrating lymphocytes, and that those tumor-infiltrating lymphocytes will actually recognize tumor antigens, but be somewhat exhausted. And that’s why the patient has had tumor growth. If we can expand those…
We completed a geospatial epidemiological study, examining colorectal cancer mortality among those diagnosed before the age of 50. And this is also known as young onset colorectal cancer. So rates of young onset, colorectal cancer, incidents and mortality have been rising rapidly since the mid-nineties with largely unknown patterns and cause. We used data from the underlying cause of death database from CDC wonder for the years, 1999 to 2019 to identify geographic hot and cold spots of young onset colorectal cancer mortality in us counties. So, the overarching result that we found was that geographic patterns of mortality among…
This study led us to the discovery of 53 gene signatures called IMPRINT and with the data we used to develop the signature. We could prove that they could identify patients’ HER2 positive and HER2 negative that could benefit from PD-1 inhibitors. We run a sub-analysis of an I-SPY dataset I-SPY2 is a phase 2 adaptive clinical trial. And we did validate our findings on our independent test set. And when we validate the accuracy of our signature in predicting patient that respond to immunotherapy. We could see that the senior tool had a very high, positive, predictive values about…
APDS or activated PI3KK delta syndrome is a relatively new disease that was only fully characterized in 2013. It is a primary immune dysregulatory disorder which means it is a rare genetic disorder that involves both immune deficiency which shows up as frequent infections and immune dysregulation which can involve things like autoimmunity lymphoproliferation symptoms can vary widely from person to person and in general it’s a progressive disease and can lead to end organ damage as well as malignancies including lymphomas in multiple family members before we get to challenge of treating a disease rare orphan disease like this…
In this interview, I will present the results of a translational analysis of the Italian drug study. AtezoTRIBE is a phase two comparative randomized study, which metastatic colorectal cancer patients were randomized to receive a first line for FOLFOXIRI plus bevacizumab with or without atezolizumab the study method, the primary endpoint showing that the addition of atezolizumab FOLFOXIRI plus Bev prolongs progression-free survival in the overall population, a modest clinical benefit is reported or among patients with proficient is match repair tumors. This results also lead to the search for predictors of benefit from this therapeutic approach. In this perspective…
This study that we presented at ASCO is titled a descriptive study on the treatment and outcomes of patients with platinum sensitive advanced BRCA or PALB2 related pancreatic cancers who have progressed on recappery so basically what this study was is a follow-up study to a phase two clinical trial of patients with platinum sensitive advanced pancreatic cancer who had a germline or somatic pathogenic variant in BRCA1, BRCA2 or PALB2 patients who had who had platinum sensitive disease where were placed on a maintenance recap rib treatment which is a parp inhibitor the clinical question we had was how…
Does Dexamethasone Work in Combination With Lenalidomide, Ixazomib in Newly Diagnosed Multiple Myeloma? The MM-6 Trial 15 Key Statistics from the MM-6 Trial for Multiple Myeloma Median age was 73 years (range, 48-90 years), with 81% aged >65 years; 97% had ≥1 comorbidity at the start of IRd therapy. Efficacy data after an additional 11 months of follow-up (data cut-off: May 4, 2021) showed that iCT to IRd improved responses. Overall response rate (ORR) had improved from 65% (CR 9%, VGPR 25%, PR 32%), at the end of 3 cycles of V-based induction, to 78% (molecular CR [mCR] 1%, stringent…
 Article: Transcript: Question – Please Tell Us About The EA 2142 Trial  So, at ASCO 2022 this year I had the opportunity to present the results of the EA 2142 clinical trial this is a randomized phase two study of platinum and a etoposide versus temozolomide and Capecitabine in patients with advanced G3 non-small cell Gastroenteropancreatic  📺 Click to Watch Video 🔊 Click for Audio Only  neuroendocrine neoplasms including both great grade three neuroendocrine tumors and grade 3 neuroendocrine carcinomas so really the reason for this trial being done is that as you’re probably aware high…
 Well this is a study to answer a very basic question that people have who are taking care of individuals at increased risk of anal cancer you know cancer is a very bad disease it causes a lot of mortality when cause when diagnosed late stage but even people diagnosed at early stage have a higher survival rate but the morbidity rate from the treatment is very high so whether somebody’s diagnosed early or late it’s a disease that is much better prevented than diagnosed after it has occurred HPV is the cause of anal cancer just like it…
 Article: Transcript: Question – Please Tell Us About The 27-gene IO Score Thanks, Stephanie, I appreciate the invitation to interview with you today so I’m going to talk about how the DetermaIO algorithm and qPCR assay are used to show an association with molecular features of gastric cancer that have also been previously shown to be associated with response to ICI therapies so this is important because gastric cancer is the fifth most incident  📺Click to Watch Video 🔊Click for Audio Only  cancer worldwide and the third leading cause of cancer-related death worldwide and so unfortunately most…
 CRESTONE was an international multi-site study looking at the use of Seribantumab a monoclonal antibody to HER3 in the treatment of patients with solid tumors that harbor and NRG1 fusion. The study actually is looking at patients that have been treated with at least one form of therapy prior to coming into study. And they must be adults that have a solid tumor that harbors an energy, one fusion that is found locally. The patients then receive Seribantumab weekly until they either have progression or they have unacceptable toxicities. The study actually presented 2 different things, both the safety…
Audio: So, at ASCO 2022 this year I had the opportunity to present the results of the EA 2142 clinical trial this is a randomized phase two study of platinum and a…Read Full Transcript Here Jennifer R. Eads, MD, Physician Lead GI Clinical Research, Associate Professor of Clinical Medicine, Director of the Neuroendocrine Tumor Program at the University of Pennsylvania. In this interview, she speaks about the ASCO 2022 Abstract – Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142. Overview:…
Platinum Chemotherapy: vs. Temozolomide/Capecitabine for Advanced GEPNENs: ECOG-ACRIN EA2142 Results Jennifer Eads MD By Jennifer Eads, MD So, at ASCO 2022 this year, I had the opportunity to present the statistically significant results of the EA2142 clinical trial. This is a randomized phase II study of Platinum and Etoposide (platinum chemotherapy) versus Temozolomide and Capecitabine in patients with advanced G-3 non-small cell gastroentero-pancreatic neuroendocrine neoplasms (pancreatic neuroendocrine tumors), including both grade 3 neuroendocrine tumors and grade 3 neuroendocrine carcinomas. The reason for this trial being done is that high-grade neuroendocrine neoplasms are a relatively rare disease entity, and there really…
Well this is a study to answer a very basic question that people have who are taking care of individuals at increased risk of anal cancer you know cancer is a very bad disease it causes a lot of mortality when cause when diagnosed late stage but even people diagnosed at early stage have a higher survival rate but the morbidity rate from the treatment is very high so whether somebody’s diagnosed early or late it’s a disease that is much better prevented than diagnosed after it has occurred HPV is the cause of anal cancer just like it is…
Well this is a study to answer a very basic question that people have who are taking care of individuals at increased risk of anal cancer you know cancer is a very bad disease it causes a lot of mortality when cause when diagnosed late stage but even people diagnosed at early stage have a higher survival rate but the morbidity rate from the treatment is very high so whether somebody’s diagnosed early or late it’s a disease that is much better prevented than diagnosed after it has occurred HPV is the cause of anal cancer just like it is…
Audio: Thanks, Stephanie, I appreciate the invitation to interview with you today so I’m going to talk about how the  DetermaIO algorithm and qPCR assay are used to…Read Full Transcript Here Matthew Varga, Ph.D., a multidisciplinary scientist with broad experience in cancer biology, infectious diseases, immunology, molecular biology, and epidemiology, Scientific Affairs at Oncocyte Corporation. In this interview, he speaks about the ASCO 2022 Abstract – The 27-gene IO score is associated with molecular features and response to immune checkpoint inhibitors (ICI) in patients with gastric cancer. Origins: Gastric cancer (GC) is the world’s third greatest cause of cancer-related death.…
DetermaIO algorithm and qPCR assay are used to show an association with molecular features of gastric cancer that have also been previously shown to be associated with response to ICI therapies so this is important because gastric cancer is the fifth most incident cancer worldwide and the third leading cause of cancer-related death worldwide and so unfortunately most gastric cancers are asymptomatic and go undiagnosed until they are in late stage and so as a result the survival outcomes for late-stage gastric cancers are exceedingly poor and so we need better treatments and detection mechanisms for identifying patients who are…
CRESTONE was an international multi-site study looking at the use of Seribantumab a monoclonal antibody to HER3 in the treatment of patients with solid tumors that harbor and NRG1 fusion. The study actually is looking at patients that have been treated with at least one form of therapy prior to coming into study. And they must be adults that have a solid tumor that harbors an energy, one fusion that is found locally. The patients then receive Seribantumab weekly until they either have progression or they have unacceptable toxicities. The study actually presented 2 different things, both the safety and…
CRESTONE was an international multi-site study looking at the use of Seribantumab a monoclonal antibody to HER3 in the treatment of patients with solid tumors that harbor and NRG1 fusion. The study actually is looking at patients that have been treated with at least one form of therapy prior to coming into study. And they must be adults that have a solid tumor that harbors an energy, one fusion that is found locally. The patients then receive Seribantumab weekly until they either have progression or they have unacceptable toxicities. The study actually presented 2 different things, both the safety and…
So, I’m talking about the AMEERA-6, which is a trial which is currently ongoing. So, we don’t yet have any data. That’s a report on the relative activity of the 2 arms, but let me describe the trial to you because this is a trial for patients, men and with potentially curable hormone receptor, positive breast cancer who are currently being treated or have recently had to stop treatment with an aromatase inhibitor because they really are struggling with the side effects. All of you who treat breast cancer patients will know that we have a significant minority of women…
So, I’m talking about the AMEERA-6, which is a trial which is currently ongoing. So, we don’t yet have any data. That’s a report on the relative activity of the 2 arms, but let me describe the trial to you because this is a trial for patients, men and with potentially curable hormone receptor, positive breast cancer who are currently being treated or have recently had to stop treatment with an aromatase inhibitor because they really are struggling with the side effects. All of you who treat breast cancer patients will know that we have a significant minority of women…
 Article: Transcript: Question – Please Tell Us About The AMEERA-6 Trial  So, I’m talking about AMEERA-6 which is a trial which is currently ongoing so we don’t yet have any data that reports on the relative activity of the two arms but let me describe the trial to you because this is a trial for patients men and women with potentially curable hormone receptor-positive breast cancer who are currently being treated or have recently had to stop  📺 Click to Watch Video 🔊 Click for Audio Only  treatment with an aromatase inhibitor because they really are…
Audio: Thank you, thanks for the question so this study titled IMP is an early phase dose-escalation study first in hand study evaluating effectiveness of a new compound called PORT-2 now PORT-2 is an invariant natural killer…Read Full Transcript Here Nicholas Coupe, MBBS, Oncologist at Oxford University Hospitals NHS Foundation Trust. In this interview, he speaks about the ASCO 2022 abstract – A phase 1 first-in-human dose-finding/randomized phase 2 study of IMM60 and pembrolizumab (PEM) in advanced melanoma and non–small cell lung cancer (NSCLC; IMP-MEL). Origins: Invariant natural killer T-cells (iNKTs) exhibit characteristics of both innate cells (NK-like) and T-cells…
INT230-6 is an early phase dose-escalation study first in hand study evaluating effectiveness of a new compound called PORT-2 now PORT-2 is an invariant natural killer T cell agonist so iNKT cells are sort of a small but important part of the immune system having influence over a number of parts and activated ion key T cells we know have positive effects upon antigen presenting cells which then in turn drives some CD8 T cell responses which are key things in anti-tumorresponses they also promote hearts the effectiveness of natural killer T cells they can also bind directly to tumorcells…
 Article: Transcript: Question – Please Tell Us About the INVINCIBLE Trial.  Thank you, thanks for the question so this study titled IMP is an early phase dose-escalation study first in hand study evaluating effectiveness of a new compound called PORT-2 now PORT-2 is an invariant natural killer T cell agonist so iNKT cells are sort of a small but important part of the immune system having influence over a number of  parts and activated ion key T cells we know  📺 Click to Watch Video 🔊 Click for Audio Only  have positive effects upon antigen presenting…
The GRIFFIN Study is a post-hoc analysis of sustained MRD negative status in the griffin study which treated patients with newly diagnosed multiple myeloma who are transplant eligible with their tumor map Lenalidomide and dexamethasone as the study arm as part of their induction consolidation after transplant and with Daratumumab (DARA) + lenalidomide as maintenance compared to the control arm which was RVd as part of their induction post-transplant consolidation and then maintenance and after all the patients completed two years of maintenance with a median follow-up of 38 years we evaluated sustained MRD negativity lasting 6 months or higher…
Audio: So the I-SPY2 trial is a neoadjuvant phase 2 study that enrolls patients with any type of breast cancer who have a tumor at least 2.5 centimeters in size and they’re randomized to receive the control which is neoadjuvant Paclitaxel..Read Full Transcript Here Laura Ann Huppert, MD, Hematology/Oncology Fellow, University of California San Francisco. In this interview, she speaks about the ASCO 2022 Abstract – Molecular subtype to predict pathologic complete response in HER2-positive breast cancer in the I-SPY2 trial. Synopsis: The goal of this study is to advance personalized medicine by learning which new drug agents are most…
Pathologic Complete Response: How may the I-SPY2 trial help HR positive HER2 negative Breast Cancer patients? Laura Huppert By Laura Huppert, MD The I-SPY2 trial is a neoadjuvant phase 2 study that enrolls patients with any type of breast cancer who have a tumor at least 2.5 centimeters in size, and they’re randomized to receive the control, which is neoadjuvant Paclitaxel, followed by AC versus an investigational agent followed by AC. And then the primary endpoint of the study is pathologic complete response rate, or PCR (pathologic complete response). And in this study we basically wanted to look at, there…
Transcript: So the I-SPY2 trial is a neoadjuvant phase 2 study that enrolls patients with any type of breast cancer who have a tumor at least 2.5 centimeters in size and they’re randomized to receive the control which is neoadjuvant Paclitaxel followed by ac versus an investigational agent followed by AC and then the primary endpoint of the study is pathologic complete response rate or PCR and the in this study we basically wanted to look at there were a thousand patients that were the 📺 Click to Watch Video 🔊 Click for Audio Only first thousand patients on the…
Audio: The FDA approval of multiple drugs um for the treatment of metastatic unresectable melanoma led to uh the concept that we should certainly interrogate whether combinations of these drugs could work synergistically together..Read Full Transcript Here Brian Gastman, MD is a double boarded Plastic Surgeon and Otolaryngologist with additional fellowships in head and neck surgery, microsurgery and cancer research. Currently, Dr. Gastman is the Medical and Surgical Director of the Melanoma & High-Risk Skin Cancer Program at Cleveland Clinic and leads his translational research laboratory at the Lerner Research Institute. In this interview, he speaks about the ASCO 2022…
T-Vec: + Pembro Advanced Melanoma MASTERKEY-115 Trial Dr Gastman By Brian Gastman, MD The FDA’s approval of multiple drugs for the treatment of metastatic unresectable melanoma led to the concept that we should certainly interrogate whether combinations of these drugs could work synergistically together. Amgen started a trial initially a different trial with their lead, intratumoral oncolytic virus T-VEC (talimogene laherparepvec), which is based on a virus that was molecularly converted to really have no viral infectious abilities, but could still replicate into tumor cells. The data for its use in patients who had never had immunotherapy with immunotherapy, specifically…
Transcript: The FDA approval of multiple drugs for the treatment of metastatic unresectable melanoma led to the concept that we should certainly interrogate whether combinations of these drugs could work synergistically together amgen started a trial initially a different trial with their lead intra-tumoral oncolytic virus t-vec which is based on a virus that was molecularly converted to really have no viral infectious abilities but could still replicate into tumor cells the the data for its use in patients who had never had immunotherapy with immunotherapy specifically anti-pd1 from pembrolizumab was an ongoing face retrial after a run-in phase one…
Audio: Hi there my name is Jia Luo I’m a thoracic medical oncologist at Dana-Farber it’s very nice to speak to you today about my talk at ASCO called Taking on Goliath Targeting K-RAS and lung cancer so the meaning behind Goliath here is..Read Full Transcript Here Jia Luo, MD, Thoracic Medical Oncologist, and Cancer Researcher at Harvard University. In this interview, she speaks about the ASCO 2022 Discussion – Taking on Goliath: Targeting Kras in Non–Small Cell Lung Cancer. 📺Click to Watch Video
KRAS Lung Cancer: Taking on Goliath Discussion by Jai Luo MD By Jai Luo, MD Hi there, my name is Jai Luo. I’m a thoracic medical oncologist at Dana Farber. It’s very nice to speak with you today about my talk at ASCO called, “Taking on Goliath: Targeting KRAS in Lung Cancer.” The meaning behind “Goliath” here is that it is a deeply difficult question, but we’ve made a ton of headway, and I think we need to take advantage of the momentum we’ve made in the field to keep advancing it forward. So, my overall takeaway from this…
Transcript: Hi there my name is Jia Luo I’m a thoracic medical oncologist at Dana-Farber it’s very nice to speak to you today about my talk at ASCO called Taking on Goliath Targeting K-RAS and lung cancer so the meaning behind Goliath here is that it is a deeply difficult question but we’ve made a ton of headway and i think we need to take advantage of the momentum we’ve made in the field to keep advancing it forward so my overall take home from this talk is that K-RAS lung cancer is common and an important question we have…
Audio: Enfortumab Vedotin was tested in a randomized phase 3 trial in patients with metastatic urothelial cancer who had previously received platinum chemotherapy and an immune checkpoint inhibitor and here we present updated data from the..Read Full Transcript Here Jonathan E. Rosenberg, MD, Chief, Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center and Professor of Medicine, Weill Cornell Medical College at Memorial Sloan Kettering Cancer. In this interview, he speaks about the ASCO 2022 Abstract – Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial…
Video: Enfortumab Vedotin was tested in a randomized phase 3 trial in patients with metastatic urothelial cancer who had previously received platinum chemotherapy and an immune checkpoint inhibitor and here we present updated data from the..Read Full Transcript Here Jonathan E. Rosenberg, MD, Chief, Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center and Professor of Medicine, Weill Cornell Medical College at Memorial Sloan Kettering Cancer. In this video, he speaks about the ASCO 2022 Abstract – Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial…
Enfortumab Vedotin was tested in a randomized phase 3 trial in patients with metastatic urothelial cancer who had previously received platinum chemotherapy and an immune checkpoint inhibitor and here we present updated data from the 24-month two-year follow-up for patients with advanced disease and I think the state is very important because it shows us that there are a proportion of patients who have durable responses the the survival rate at five years for metastatic bladder cancer has historically been around five percent and this and we’ve certainly seen some improvements although still not where it needs to be the…
Transcript – KEYNOTE-716 New Facts You Need To Know – Article Question – Please Tell Us About The KEYNOTE-716 Study. At ASCO 2022 I presented the first analysis of the distant metastasis free survival in the keynote 716 study so this is a study of patients with resected stage 2b and 2c melanoma this is a patient group who actually have a very high risk of recurrence by 24 months many patients have recurred and their prognosis at five years is very poor with a poor overall survival so seven uh 976 patients were randomized one to one with resected…
Transcript – Where is the Elaine 2 Study and Just-in-time Model Right Now? – Article Question – Please Tell Us About The ELAINE II Study. So this was an open label phase two multi-center study looking at Lasofoxifene (LAS) in combination with Abemaciclib (Abema) for treating postmenopausal women with locally advanced or metastatic er positive HER2 negative breast cancer with an ESR1 mutation and this was after progression on prior therapies so as a background ESR1 mutations are a common mechanism of resistance to aromatase inhibitor (AI) therapy and have been associated with poor prognosis in metastatic hormone receptor positive…
Audio: Open label phase 2 multi-center study looking at Lasofoxifene (LAS) in combination with a Abemaciclib (Abema) for treating postmenopausal women with locally advanced or metastatic ER+ HER2 negative breast cancer with an ESR1 mutation..Read Full Transcript Here Halle Moore, MD, Associate Professor, Department of Medicine, School of Medicine, Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center at Cleveland Clinic. In this video, she speaks about the ASCO 2022 Abstract – Â Open label phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre-and postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer and…
Video: Open label phase 2 multi-center study looking at Lasofoxifene (LAS) in combination with a Abemaciclib (Abema) for treating postmenopausal women with locally advanced or metastatic ER+ HER2 negative breast cancer with an ESR1 mutation..Read Full Transcript Here Halle Moore, MD, Associate Professor, Department of Medicine, School of Medicine, Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center at Cleveland Clinic. In this video, she speaks about the ASCO 2022 Abstract – Â Open label phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre-and postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer and…
Chirag Shah, MD, Director of Breast Radiation Oncology and Director of Clinical Research in the Department of Radiation Oncology at Cleveland Clinic. In this audio, he speaks about the ASCO 2022 Abstract – Assessing the benefit of adjuvant endocrine therapy in patients following breast-conserving surgery with or without radiation stratified by a 7-gene predictive DCIS biosignature.Â
DCISionRT: Assessing Breast Cancer Adjuvant Endocrine Therapy After BCS Chirag Shah MD By Chirag Shah, MD So this study was an analysis of 926 patients who had undergone breast conserving surgery, with or without radiation therapy and with or without endocrine therapy. They were diagnosed with ductal carcinoma in situ and this came from four groups of patients that were put together. These patients had the DCISionRT assay run on them, and they were broken up into three groups. One was the low-risk group, which was a DCISionRT score of less than or equal to 2.8. One was the elevated…
Aaron T. Gerds, MD, MS, Associate Professor of Medicine, Deputy Director for Clinical Research at the Cleveland Clinic Taussig Cancer Institute and Medical Director of the Case Comprehensive Cancer Center Clinical Research Office at Cleveland Clinic. In this audio, he speaks about the EHA 2022 abstract A Real-World Evaluation of the Association Between Elevated Blood Counts and Thrombotic Events in Polycythemia Vera: An Analysis of Data from the REVEAL Study. Outline Back story PV is characterized by clonal hematopoiesis, which results in higher peripheral blood counts and an increased risk of thrombotic events (TEs). The standard risk model used to…
At this year’s EHA meeting, we presented an abstract from the REVEAL study. Really focusing in on thrombosis risk in patients with polycythemia vera, with respect to their blood counts outside of the adequate the REVEAL study is a very large prospective observational study of patients with polycythemia vera treated in both. Community practices as well as academic practices. And it is a cross-sectional study where we enrolled 2,500 patients, again, four observations. So, there was no therapeutic intervention there. And they were followed for a minimum of 36 months after enrollment. So, we got a pretty good broad swipe…
Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, Haematologist with clinical and research interests in multiple myeloma, in particular myeloma, lymphoma and myeloid disorders at St Vincent’s Health Melbourne  and University of Melbourne Australia. In this audio, she speaks about the EHA 2022 Abstract – Carfilzomib, Dexamethasone, And Daratumumab (Kdd) Vs Carfilzomib And Dexamethasone (Kd) In Relapsed/Refractory Multiple Myeloma (Rrmm): Frailty Subgroup Analysis Of The CANDOR Study. History Frailty scores based on age, comorbidities, and functional status can assist in identifying frail patients (pts) at risk of treatment-related toxicity or poor outcomes. An examination of carfilzomib-treated patients in the clinical trials…
The study that I will be discussing today is the frailty subgroup analysis of the CANDOR study, which is a phase 3 study comparing Daratumumab, Carfilzomib and Dexamethasone. That’s Dara KD with KD that’s Carfilzomib and Dexamethasone in patients with relapse refractory, multiple myeloma. Now in the treatment of multiple myeloma sometimes efficacious treatment can result in poor outcome. If patients are FRA and cannot tolerate treatment now we know from the phase three can or study that the triplet combination of Dara KD is effective and result in a 41% relative risk reduction in progression or death compared to…